Assessment of Pentraxin 3 (PTX3) and Sclerostin (SOST) Levels in Serum of Patients with Chronic Kidney Disease

Abstract

In the present study, 70 of patients were 35 males and 35 females were suffering from chronic kidneydisease, and 20 of control group. The samples were collected from Specialized Center for Diseases andKidney Transplant in AL-Sadder Medical City/Najaf Governorate/Iraq, during the period from July tillAugust, 2019. The ages of control and patients ranged 30 to 69 y old. The patients group was divided intosubgroup according to the age and gender, Patients without a complete medical record were excluded andthose with other diseases were excluded.The present study revealed a significant enhance (p<0.05) inserum PTX3 and SOST levels in CKD comparewith control group, while a significant decline (P<0.05) in serum HDL level of CKD in comparison withcontrol group. The result indicated no significant differences (p>0.05) in serum of PTX3 and SOST levelsbetween female and males groups of CLD patients. Also, The results showed a significant increase (p>0.05)in serum PTX3 and SOST levels there was a significant increase(p<0.05)among different groups ages. Thereis a positive association between PTX3 and SOST concentrations of CKD patientsConclusion: The current study conducted that PTX3 and SOST levels were good markers for diagnosis anddetection of chronic kidney disease in both genders the males and females.